Elaine Blais, JD, partner at Goodwin and head of the litigation department in Goodwin’s Boston office, discusses whether the US patent system is likely to see reform in the near future.
Transcript
I think it’s likely that we’ll see significant proposals around patent reforms from some of the discussions that are going on at this point. I think it’s unlikely that we’ll see significant reforms anytime soon. And I say that not because I’m making a substantive decision about whether reforms are needed, but because history tells us that patent reform is slow and methodical, and I don’t expect it to be any different here.
The issue with patent reform is [that] one stakeholder’s dream reform might be a nightmare to another stakeholder. And we know from our prior iterations of patent reform that there will be many of discussions, lots of attempts to balance out interests of different parties, and especially in this Congress where there’s a lot of disagreement, I think it could be a lot of delay before we see anything significant happening in Congress. Looking to the courts is probably going to be a better opportunity for reforms that will have an impact on [Biologics Price Competition and Innovation Act, BPICA] litigation.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.